JP2016521695A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521695A5 JP2016521695A5 JP2016517101A JP2016517101A JP2016521695A5 JP 2016521695 A5 JP2016521695 A5 JP 2016521695A5 JP 2016517101 A JP2016517101 A JP 2016517101A JP 2016517101 A JP2016517101 A JP 2016517101A JP 2016521695 A5 JP2016521695 A5 JP 2016521695A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fibrosis
- och
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C(C(*)C(C(O)=O)N)=O Chemical compound C*C(C(*)C(C(O)=O)N)=O 0.000 description 3
- FBZONXHGGPHHIY-UHFFFAOYSA-N OC(c1cc(O)c(cccc2O)c2n1)=O Chemical compound OC(c1cc(O)c(cccc2O)c2n1)=O FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831404P | 2013-06-05 | 2013-06-05 | |
| US61/831,404 | 2013-06-05 | ||
| PCT/CA2014/000484 WO2014194407A1 (en) | 2013-06-05 | 2014-06-04 | Anti-fibrogenic compounds, methods and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521695A JP2016521695A (ja) | 2016-07-25 |
| JP2016521695A5 true JP2016521695A5 (cg-RX-API-DMAC7.html) | 2017-07-20 |
| JP6473938B2 JP6473938B2 (ja) | 2019-02-27 |
Family
ID=52007349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517101A Active JP6473938B2 (ja) | 2013-06-05 | 2014-06-04 | 抗線維化化合物、その方法および使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9737523B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3003298B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6473938B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102294405B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014277568B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2914261C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3003298T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2978920T3 (cg-RX-API-DMAC7.html) |
| PH (1) | PH12015502717B1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3003298T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2726416C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201510003VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014194407A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201600015B (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10779517B2 (en) | 2017-01-31 | 2020-09-22 | The Board Of Regents Of The University Of Oklahoma | Animal wound model and methods of use |
| CN112168822B (zh) * | 2020-09-27 | 2022-11-08 | 集美大学 | 犬尿酸在改善高脂饮食致血脂异常、肥胖、肠道菌群混乱中的用途 |
| JP2024517463A (ja) * | 2021-05-04 | 2024-04-22 | ソヴィダ ソリューションズ リミテッド | ニコチンアミドアデニンジヌクレオチド（ｎａｄ）組成物、それらの製造方法、及びそれらの使用方法 |
| US20240226085A1 (en) * | 2021-05-07 | 2024-07-11 | Birchbiomed Inc. | Kynrenine and derivatives thereof for treating atrophic scarring |
| CN119055650A (zh) * | 2024-09-06 | 2024-12-03 | 上海市东方医院（同济大学附属东方医院） | 犬尿喹啉酸在治疗慢性肝硬化中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| EP1369114A1 (en) * | 2002-06-07 | 2003-12-10 | Peter Priv. Doz. Dr. Terness | Use of tryptophan metabolites as pharmaceutical agents |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2005306585A1 (en) * | 2004-11-17 | 2006-05-26 | Nuon Therapeutics Pty Limited | A method of modulating B cell functioning |
| HUP0700051A2 (en) * | 2007-01-17 | 2008-09-29 | Univ Szegedi | Use of kynurenic acid and derivatives there of for treating of gastrointestinal disorders associated with enhanced motility and inflammation |
| SMT202100248T1 (it) * | 2012-06-15 | 2021-05-07 | Conaris Res Institute Ag | Composizione farmaceutica contenente acido nicotinico e/o nicotinammide e/o triptofano per influenzare positivamente il microbiota intestinale |
-
2014
- 2014-06-04 DK DK14806967.7T patent/DK3003298T3/da active
- 2014-06-04 KR KR1020167000203A patent/KR102294405B1/ko active Active
- 2014-06-04 AU AU2014277568A patent/AU2014277568B2/en active Active
- 2014-06-04 ES ES14806967T patent/ES2978920T3/es active Active
- 2014-06-04 PL PL14806967.7T patent/PL3003298T3/pl unknown
- 2014-06-04 CA CA2914261A patent/CA2914261C/en active Active
- 2014-06-04 WO PCT/CA2014/000484 patent/WO2014194407A1/en not_active Ceased
- 2014-06-04 JP JP2016517101A patent/JP6473938B2/ja active Active
- 2014-06-04 PH PH1/2015/502717A patent/PH12015502717B1/en unknown
- 2014-06-04 US US14/896,269 patent/US9737523B2/en active Active
- 2014-06-04 RU RU2015156196A patent/RU2726416C2/ru active
- 2014-06-04 SG SG11201510003VA patent/SG11201510003VA/en unknown
- 2014-06-04 EP EP14806967.7A patent/EP3003298B1/en active Active
-
2016
- 2016-01-04 ZA ZA2016/00015A patent/ZA201600015B/en unknown